AliveDx Suisse S.A. and Bio-Strategy, part of DKSH Group, have signed a distribution agreement, which will enable Bio-Strategy to distribute the LumiQ™ solution in Australia and New Zealand. The distribution agreement takes effect immediately.
This partnership underscores AliveDx’s dedication to broadening its global footprint and delivering clinical and economic value to clinicians, aiding in faster diagnosis. This collaboration will allow both parties to launch new quality services in the healthcare industry and improve patient care in Australia and New Zealand.
The LumiQ solution will enhance the MosaiQ® solution currently being distributed by Bio-Strategy in Australia and New Zealand. The MosaiQ solution is a groundbreaking IVD platform for autoimmune diseases, allergies, and beyond. Its multiplexed, fully automated planar microarray technology enables syndromic testing for complex conditions. Designed for high throughput with continuous random access, the MosaiQ solution delivers fast, accurate results to meet the evolving demands of laboratory efficiency. When combined with the LumiQ solution, these platforms provide a seamlessly integrated, turnkey approach to screening and confirming autoantibodies across a wide range of diseases, simplifying workflows and enhancing efficiency.
“We are proud to announce our partnership with a key player in Australia and New Zealand. We are eager to collaborate with Bio-Strategy and to make a strategic impact on improving patients’ lives throughout the region,” said Manuel O. Méndez, CEO of AliveDx.
Bio-Strategy was founded in 2003 and became part of the DKSH Group in 2023. It is an established ISO9001:2015 accredited distributor delivering technology to the Scientific Community throughout Australasia. The company, headquartered in Melbourne, Australia, provides quality technology to customers in market sectors including Diagnostic Laboratories, Academic Research, Government Institutes, Applied Testing and Industry.
“We are thrilled to partner with AliveDx as part of our mission to expand our diagnostic business portfolio. Adding this second AliveDx solution marks a significant milestone in our growth within the clinical diagnostics sector. The combination of the MosaiQ and LumiQ technologies will enable us to introduce groundbreaking solutions to the healthcare sectors of Australia and New Zealand, making a positive and lasting impact on patient care,” said Richard Speight, PhD, General Manager, Bio-Strategy Australia & New Zealand.
To learn more, please visit the Bio-Strategy website.
